TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective

Related articles

1. TPD52 promotes breast cancer cell migration, invasion and proliferation via activation of the MAPK/ERK signaling pathway

   This article has 8 authors:

   1. Jiahui Yu
   2. Zhenyu Zhu
   3. Renhe Deng
   4. Min Chen
   5. Xihong Deng
   6. JieLei Zhu
   7. Jiankang Zhou
   8. Xue Li

2. Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy

   This article has 8 authors:

   1. Djansel Bukovec
   2. Marija Gjorgjievska
   3. Sara Kocevska
   4. Mia Nikolova
   5. Lina Mirkovikj
   6. Ivan Kungulovski
   7. Zan Mitrev
   8. Goran Kungulovski

3. CAST as a Tumor-Specific Suppressor in Colorectal Cancer: Discovery Through Integrative Analysis of Unannotated Isoforms, Proteomics, and Epigenetic Regulation

   This article has 2 authors:

   1. Alireza Ebadi
   2. Maryam Hashemi